| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The HA epitope is not a drug targeting a biological receptor. Instead, it serves as an antigenic tag that binds with high affinity to anti-HA antibodies (e.g., clone 12CA5 or 16B12). Its target is the antibody paratope in immunoassays.
|
|---|---|
| ln Vitro |
In vitro, the HA epitope shows specific binding to anti-HA antibodies in ELISA, Western blot, and immunoprecipitation assays. It does not possess intrinsic enzymatic or signaling activity but functions solely as a recognition motif for antibody-based detection.
|
| ln Vivo |
There is no in vivo activity for this peptide as a drug. When fused to a protein of interest, the HA tag allows in vivo tracking of that protein using anti-HA antibodies, but the tag itself has no pharmacological effect in animals.
|
| Enzyme Assay |
General protocol: Microplate wells are coated with anti-HA antibody. The HA-tagged protein or free HA peptide is added. After washing, a secondary HRP-conjugated antibody is added, followed by substrate for colorimetric detection. Binding affinity is measured by SPR.
|
| Cell Assay |
General protocol: Cells are transfected with a plasmid encoding an HA-tagged protein of interest. After 24-48 hours, cells are lysed, and the HA tag is detected by Western blot using an anti-HA primary antibody and HRP-conjugated secondary antibody. Immunofluorescence is also common.
|
| Animal Protocol |
Not applicable for the peptide alone. However, in vivo studies using HA-tagged proteins involve expressing the tagged protein in animal models (e.g., via viral vectors). Tissue sections are then stained with anti-HA antibodies to localize the protein of interest.
|
| ADME/Pharmacokinetics |
Not applicable as the HA epitope is not a therapeutic agent. As a peptide, it is rapidly degraded by proteases in vivo, with a half-life of minutes. It is not designed for systemic exposure or pharmacokinetic profiling.
|
| Toxicity/Toxicokinetics |
The HA epitope peptide itself is non-toxic at typical research concentrations (microg/mL to mg/mL). It may cause minor immune responses if injected as a foreign peptide, but it is generally considered safe for laboratory use.
|
| References |
[1]. Wedaman KP, et al. Tor kinases are in distinct membrane-associated protein complexes in Saccharomyces cerevisiae. Mol Biol Cell. 2003 Mar;14(3):1204-20.
|
| Additional Infomation |
This peptide is a standard molecular biology tool, not a drug. It has no clinical trials or approved therapeutic status. It is used in research applications including protein pull-downs, ChIP-seq, and super-resolution microscopy for protein localization.
|
| Exact Mass |
1204.475
|
|---|---|
| CAS # |
92000-72-1
|
| PubChem CID |
168355667
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
15
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
29
|
| Heavy Atom Count |
85
|
| Complexity |
2380
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](CS)N
|
| InChi Key |
DJQPKBDJPGAMFB-QFKGLCFGSA-N
|
| InChi Code |
InChI=1S/C56H72N10O18S/c1-28(2)46(55(82)66-21-5-7-43(66)53(80)62-39(25-44(70)71)50(77)59-37(48(75)58-29(3)56(83)84)22-30-8-14-33(67)15-9-30)64-51(78)40(26-45(72)73)60-49(76)38(23-31-10-16-34(68)17-11-31)61-52(79)42-6-4-20-65(42)54(81)41(63-47(74)36(57)27-85)24-32-12-18-35(69)19-13-32/h8-19,28-29,36-43,46,67-69,85H,4-7,20-27,57H2,1-3H3,(H,58,75)(H,59,77)(H,60,76)(H,61,79)(H,62,80)(H,63,74)(H,64,78)(H,70,71)(H,72,73)(H,83,84)/t29-,36-,37-,38-,39-,40-,41-,42-,43-,46-/m0/s1
|
| Chemical Name |
(3S)-3-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-oxobutanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (82.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
